Sunifiram Powder

Sunifiram Powder

Introduction

Sunifiram (DM235) is a nootropic compound structurally related to piracetam. It is known for its potential cognitive-enhancing properties. In its tablet form, Sunifiram is a subject of scientific research for its impact on memory, learning, and pain sensitivity.

Key Characteristics

Sunifiram is characterized by its structural similarity to other nootropics and its ability to modulate neurotransmitter systems, particularly glutamate receptors. As a research compound, it is recognized for its potential influence on cognitive processes.

Research Applications

Sunifiram powder has been investigated for its applications in neuroscience and cognitive research. Researchers explore the compound’s effects on memory, learning, and pain perception while seeking to understand its mechanisms of action.

Research Benefits

Sunifiram and Memory

Studies have suggested that Sunifiram may have a positive impact on memory functions. Research has delved into its potential as a cognitive enhancer, aiming to uncover the molecular processes underlying its effects on memory.

Sunifiram and Learning

Scientific inquiry has explored the potential of Sunifiram in facilitating learning processes. Studies aim to elucidate how the compound interacts with neuronal pathways to enhance learning abilities.

Sunifiram and Pain Sensitivity

Research has investigated the role of Sunifiram in modulating pain sensitivity. Studies explore its impact on pain perception, offering insights into the compound’s potential involvement in nociception processes.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Moriguchi S, Tanaka T, Tagashira H, Narahashi T, Fukunaga K. The novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice. Behav Brain Res. 2013 Apr 1;242:150-7. doi: 10.1016/j.bbr.2012.12.054. Epub 2013 Jan 4. PMID: 23295391. [Read More].
2. Martini E, Norcini M, Ghelardini C, Manetti D, Dei S, Guandalini L, Melchiorre M, Pagella S, Scapecchi S, Teodori E, Romanelli MN. Design, synthesis, and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators. Bioorg Med Chem. 2008 Dec 1;16(23):10034-42. doi: 10.1016/j.bmc.2008.10.017. Epub 2008 Oct 11. PMID: 18954993. [Read More].
3. Manetti D, Ghelardini C, Bartolini A, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Teodori E. Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. J Med Chem. 2000 Nov 16;43(23):4499-507. doi: 10.1021/jm000972h. PMID: 11087574. [Read More].